Milestone Pharmaceuticals Stock Today
| MIST Stock | USD 1.90 0.05 2.56% |
PerformanceWeak
| Odds Of DistressVery High
|
Milestone Pharmaceuticals is selling for under 1.90 as of the 23rd of March 2025; that is 2.56 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 1.87. Milestone Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of May 2019 | Category Healthcare | Classification Health Care |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company was incorporated in 2003 and is headquartered in Montral, Canada. Milestone Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 53.35 M outstanding shares of which 398.73 K shares are now shorted by private and institutional investors with about 0.71 trading days to cover. More on Milestone Pharmaceuticals
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Milestone Stock Highlights
| President CEO | Joseph MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMilestone Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Milestone Pharmaceuticals' financial leverage. It provides some insight into what part of Milestone Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Milestone Pharmaceuticals (MIST) is traded on NASDAQ Exchange in USA. It is located in 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6 and employs 33 people. Milestone Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 101.37 M. Milestone Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 53.35 M outstanding shares of which 398.73 K shares are now shorted by private and institutional investors with about 0.71 trading days to cover.
Milestone Pharmaceuticals currently holds about 86.24 M in cash with (28.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Milestone Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationMilestone Pharmaceuticals maintains a total of 53.35 Million outstanding shares. 30% of Milestone Pharmaceuticals outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Milestone Ownership Details
Milestone Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| The Toronto-dominion Bank | 2024-12-31 | 750 K | |
| Citadel Advisors Llc | 2024-12-31 | 608.2 K | |
| Stonepine Capital Management Llc | 2024-12-31 | 500 K | |
| Ikarian Capital, Llc | 2024-12-31 | 466 K | |
| Boxer Capital Management, Llc | 2024-12-31 | 309 K | |
| Boxer Capital Llc | 2024-09-30 | 309 K | |
| Ubs Group Ag | 2024-12-31 | 89.5 K | |
| Virtu Financial Llc | 2024-12-31 | 72 K | |
| Envestnet Asset Management Inc | 2024-12-31 | 63.7 K | |
| Blackrock Inc | 2024-12-31 | 4.1 M | |
| Millennium Management Llc | 2024-12-31 | 2.7 M |
Milestone Pharmaceuticals Historical Income Statement
Milestone Stock Against Markets
Milestone Pharmaceuticals Corporate Management
| Anita Holz | VP Affairs | Profile | |
| Jeff Moore | Vice Sales | Profile | |
| Guy Rousseau | SVP Management | Profile | |
| FACC FAHA | Chief Board | Profile | |
| Jeffrey Nelson | Chief Officer | Profile | |
| Roshan Girglani | Vice Marketing | Profile |
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.